Cosmos Pharmaceutical Limited | OMECOS®Capsules
Cosmos Limited is one of the leading manufacturers of pharmaceutical products in Kenya and East Africa. Through our specialized Human Health and Animal Health.
Cosmos Limited,top pharmaceutical,top pharma,best pharma,best pharmaceutical,leading pharma,leading pharmaceutical,pharma,cosmos pharmaceutical,cosmos,cosmos Kenya,top pharmaceutical,best pharmaceutical,leading pharmaceutical,medicine,veterinary,animal health,human health,company,companies,manufacturer in Kenya,manufacturers in Kenya,Delvin Mugo,Mugo Delvin,manufacturers in east Africa,manufacturers in Africa ,Cosmos, cosmos pharmaceuticals,pharmaceuticals, pharmaceutical,pharmaceutical company in Kenya,pharmaceuticals companies in Kenya,pharmaceutical company in Nairobi, pharmaceuticals companies in Nairobi,pharmaceuticals companies Nairobi,Kenya pharmaceuticals companies,Nairobi pharmaceuticals,top pharma,best pharma,leading pharma,pharma,top pharmaceutical,best pharmaceutical,leading pharmaceutical,medicine,veterinary,animal health,human health,Kenya pharmaceutical,best medicine,Kenya best medicine,Nairobi manufacturer,best manufacturer,profitable company in Kenya,company,companies,manufacturer in Kenya,manufacturers in Kenya,manufacturers in east Africa,manufacturers in Africa,pharmacy in Kenya,pharmaceutical supplies in Kenya,pharmacies in Kenya,chemists in Kenya,chemist in Kenya,pharmaceutical companies in Kenya,leading pharmaceutical in Kenya, best pharmaceutical in Nairobi,best pharmaceutical in Kenya, pharmaceuticals companies Nairobi, pharmaceuticals companies Kenya, pharmaceuticals products distributor in Nairobi, pharmaceuticals products distributor in Kenya,Kenya Quality Healthcare Products, Quality Healthcare Products,A renown Pharmaceutical company in Kenya,A renown Pharmaceutical
17926
page-template,page-template-full_width,page-template-full_width-php,page,page-id-17926,ajax_updown_fade,page_not_loaded,,side_area_uncovered_from_content,overlapping_content,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-theme-ver-13.1.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.5,vc_responsive
 

OMECOS®Capsules

CLINICAL PHARMACOLOGY:

Omeprazole inhibits secretion of gastric acid by irreversibly blocking the enzyme system of hydrogen/potassium adenosine triphosphatase (H+/K+ATPase), the ‘proton pump’ of the gastric parietal cell.

Pharmacokinetics:

Omeprazole is rapidly but variably absorbed after oral administration. Absorption of Omeprazole is not affected by food. Omeprazole is acid-labile and various formulations have been developed in an attempt to improve bioavailability from the gastro-intestinal tract. The absorption of Omeprazole, as well as being formulation-dependent, also appears to be dose-dependent, as increasing the dosage above 40mg has been reported to increase the plasma concentrations in a non-linear fashion. Bioavailability of Omeprazole may be increased in elderly patients and in patients with impaired hepatic function, but is not markedly affected in patients with renal impairment. Following absorption, Omeprazole is almost completely metabolised in the liver, primarily by cytochrome P450 isoenzyme CY2C19, and rapidly eliminated, mostly in the urine. Although the elimination half-life from plasma is short, being reported to be about 0.5 to 3 hours, its duration of action with regard to inhibition of acid secretion is much longer allowing it to be used in single daily doses. Omeprazole is highly bound (about 95%) to plasma proteins.

USES:

Omecos® is used in conditions where inhibition of gastric acid secretion may be beneficial, including aspiration syndrome, dyspepsia, gastro-oesophageal reflux disease, peptic ulcer disease, and the Zollinger-Ellison Syndrome.

DOSAGE AND ADMINISTRATION:

For the relief of acid-related dyspepsia: 10 or 20mg daily by mouth for 2 to 4 weeks.
For the treatment of gastro-oesophageal reflux disease: 20 to 40mg by mouth once daily for 4 to 12 weeks; thereafter maintenance therapy can be continued with 20mg once daily.
Children: 0.7 to 1.4mg per kg body-weight daily, up to a maximum daily dose of 40mg for 4 to 12 weeks.
The management of peptic ulcer disease: A single daily dose of 20mg by mouth, or 40mg in severe cases, is given. Treatment is continued for 4 weeks for duodenal ulcer and 8 weeks for gastric ulcer. A dose of 10 to 20mg once daily may be given for maintenance.
Zollinger-Ellison Syndrome: 60mg by mouth once daily. Doses above 80mg should be divided and given twice daily; treatment should be continued for as long as is clinically indicated.
Prophylaxis of acid aspiration: 40mg in the evening before surgery, and a further 40mg on the day of surgery 2 to 6 hours before the procedure.
OMECOS® CAPSULES

CONTRA-INDICATIONS AND  WARNINGS:
Precautions
:

Before giving Omeprazole to patients with gastric ulcers the possibility of malignancy should be considered since Omeprazole may mask symptoms and delay diagnosis. Omeprazole is extensively metabolised in the liver and dosage should be reduced in hepatic impairment.

Adverse Effects:

Adverse effects reported most frequently are gastro-intestinal disturbances, in particular diarrhoea, skin rashes, and headache. Effects on the CNS, including reversible confusional states, agitation, depression, and hallucinations in severely ill patients, have occurred. Other adverse effects reported rarely include arthralgia and myalgia, paraesthesia, aggression, blurred vision, taste disturbances, peripheral oedema, hyponatraemia, blood disorders including agranulocytosis, leucopenia and thrombocytopenia, interstitial nephritis and hepatotoxicity.

Interactions:

Omeprazole and other proton pump inhibitors are metabolised by the cytochrome P450 system, primarily by isoenzyme CYP2C19, and may alter the metabolism of some drugs metabolised by these enzymes. Omeprazole may prolong the elimination of diazepam, phenytoin, and warfarin but see  and other proton  pump inhibitors can reduce the absorption of drugs such as ketoconazole, and possibly itraconazole, whose absorption is dependent on an acid gastric pH. With voriconazole, the plasma concentration of both drugs may be increased and a reduced dose of omeprazole is recommended.

PHARMACEUTICAL PRECAUTIONS:

Store in a dry place below 25°C. Protect from light.  Keep all medicines out of the reach of children.

LEGAL CATEGORY:
Prescription Only Medicine (POM)
®Regd. TM    Ref. No. INS138/08.06

IMAGES
  • OMECOS®Capsules

    PresentationWhite pellets filled in Pink/Maroon hard gelatin capsule printed COSMOS/OMECOS - 20 on body and cap. Each capsule contains: Omeprazole 20mg .Pack size - 30's (3x10's)